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Abstract 
Introduction: We investigated the impact of long-term levothyroxine (LT4) treatment 
on bone mineral density (BMD) and bone turnover markers (BTMs) in premenopausal 
women with differentiated thyroid cancer (DTC) after thyroidectomy. 
Material and methods: Sixty-five premenopausal women who received LT4 therapy 
at least one year (range, 1.5–9.0 years) after thyroidectomy for DTC and 50 
premenopausal women without thyroid diseases were enrolled in this study. We 
measured the Z-scores of lumbar and hip BMD, serum free triiodothyronine (FT3), free 
thyroxine (FT4), thyroid-stimulating hormone (TSH), intact parathyroid hormone 
(iPTH), N-terminal propeptide of type 1 N procollagen (P1NP), C-terminal telopeptide 
of type 1 collagen (CTX-1), calcium (Ca), phosphorus (P), vitamin D (3), and alkaline 
phosphatase (ALP) in all participants. 
Results: In DTC subjects, serum TSH levels were lower, and serum FT4, P1NP, CTX-
1, and ALP levels were higher compared with controls. The prevalence of low BMD 
was higher in DTC subjects than in controls. Multivariate logistic regression analysis 
showed that serum TSH levels were negatively associated with CTX-1 and ALP.  
Conclusions: We found a high prevalence of low BMD among premenopausal women 
who received long-term LT4 therapy for DTC after thyroidectomy. Long-term TSH 
suppression therapy was a significant risk factor for decreased bone strength, mainly 
by increasing bone turnover. 
Key words: levothyroxine; bone mineral density; women; bone turnover markers; 
thyroid cancer; thyroidectomy 
 
Introduction 
Thyroid cancer is one of the most common endocrine malignancies. The incidence of 
DTC has increased substantially in the last four decades [1–3]. Most of the thyroid 
cancer raised from thyroid follicular epithelial cells, a well-differentiated cancer, have 
an excellent prognosis, with reported 10-year survival rates reaching 90% [4, 5]. If the 
treatment according to the current guideline is given, cases of recurrence and 
persistence are rare [6–8]. After diagnosis, patients with thyroid cancer will generally 
undergo total or near total thyroidectomy. These patients, after thyroidectomy, will be 
treated with long-term LT4 for TSH suppression in order to inhibit cancer recurrence. 
For the first two years the serum TSH levels are required to be < 0.1 mIU/L. If there 
was no recurrence in the first year or if the patients were low-risk recurrent, the serum 
TSH levels can be kept with 0.1–0.5 mIU/L [9, 10]. This means that most of the patients 
receiving TSH suppression treatment are in a state of hyperthyroidism or subclinical 
hyperthyroidism, with high risk of adverse effects, including cardiovascular or skeletal 
outcomes [11–13].  
Thyroid hormones are considered essential for bone metabolism in adults. Thyroid 
hormones have important effects on the balance of skeletal development and bone linear 
growth, which maintain bone mass and strength [14, 15]. Hyperthyroidism causes high 
bone turnover and shortening of the normal remodelling cycle, leading to decreased 
BMD and bone strength. Hyperthyroidism and subclinical hyperthyroidism are all well 
known risk factors for osteoporosis or osteopaenia [16–18]. The American Thyroid 
Association (ATA) recommend treating patients with levels of TSH less than 0.1 mIU/L 
if they are older than 65 years or suffer from cardiovascular diseases or osteoporosis 
[19]. However, the effect of long-term TSH suppressive therapy on BMD and BTMs in 
patients with DTC after thyroidectomy is still unclear [20–22], and most of these studies 
involved postmenopausal women, who have a higher risk of osteoporosis. In this study, 
we try to investigate the impact of long-term LT4 treatment on BMD and BTMs in 
premenopausal women with DTC after thyroidectomy. 
Material and methods 
Subjects 
From May 2018 to April 2019, we randomly selected 65 premenopausal women (aged 
32 to 45 years) with DTC from the Endocrinology Clinic of Heilongjiang Provincial 
Hospital, Harbin, China. All participants had undergone total or near total 
thyroidectomy and received LT4 therapy for at least one year in order to maintain a 
serum TSH concentration between 0.1 and 0.5 mIU/L. Mean duration of levothyroxine 
treatment was 5.25 ± 3.14 years (range, 1.5-9.0 years). The mean dosage of 
levothyroxine was 133.6 µg (range, 25–150 µg/day). At the same time, we randomly 
selected 50 premenopausal women without history of thyroid diseases (aged 29 to 45 
years) from a physical examination centre at the same hospital. We excluded 
participants with a history of alcohol abuse, asthma, severe renal or hepatic diseases, 
hyperthyroidism, hyperparathyroidism, hypoparathyroidism, hypercalcaemia, chronic 
use of corticosteroid, severe gastrointestinal diseases, malignant tumour, diabetes 
mellitus, severe cardiac diseases, rheumatoid arthritis, and other rheumatic-
inflammatory diseases from this study. Participants who underwent any treatment of 
osteoporosis or osteopaenia like selective oestrogen receptor modulators, 
bisphosphonate, and calcitonin were also excluded from this study.  
Definitions 
Premenopausal women were those aged 18–45 years with normal menstrual cycle. Low 
BMD in premenopausal women is diagnosed according to the diagnostic criteria of the 
World Health Organisation (WHO) [23]. Lumbar or hip BMD by DXA; Z score less 
than or equal to −2.0. 
 
Laboratory measurements 
The Z-scores of BMD of lumbar spine (L2–L4) and hip (femoral neck, ward triangle, 
trochanter, total hip) were measured using a dual-energy X-ray absorptiometry (DXA) 
instrument (Hologic, Inc., Bedford, MA, USA). The coefficient of variation of BMD in 
our hospital is 1.40% in the lumbar spine and 1.50% in the hip. Participants were 
measured on the same instrument, using the same scan speed and doctor. Fasting blood 
samples were obtained at least eight-hour overnight fast from all subjects. Serum CTX-
1 levels were measured by enzyme-linked immunosorbent assay (ELISA). The 
sensitivity was 1.224 ng/mL, the intra-assay coefficient of variability (CV%) was 10.05, 
and the inter-assay CV% was 10.34. Serum P1NP was measured by radioimmunoassay 
(RIA). The sensitivity was 0.842 ug/L, the intra-assay coefficient of CV% was 5.65, 
and the inter-assay CV% was 5.484. Serum FT3, FT4, TSH, iPTH, and vitamin D (3) 
levels were measured using super sensitive electrochemiluminescence immunoassays 
(Roche Diagnostics, Mannheim, Germany). The normal reference range for serum TSH 
is 0.35–4.94 mIU/L, for FT3 is 2.60–5.70 pmol/L, and for FT4 is 9.0–19.0 pmol/L. 
Serum Ca, P, and ALP levels were measured by automatic biochemical analyser 
(Hitachi, Ltd., Tokyo, Japan). The measurement of serum CTX-1, P1NP, FT3, FT4, 
TSH, iPTH, and vitamin D (3) levels was performed at the Centre of Special 
Radioimmunoassay in Heilongjiang Provincial Hospital. The measurement of serum 
Ca, P, and ALP was performed at the Department of Experimental Diagnosis in 
Heilongjiang Provincial Hospital. 
 Medical ethics approval  
This study was approved by the Medical Ethics Committee of Heilongjiang Provincial 
Hospital. Written consent to participate in this study was obtained from all participants. 
Only those who signed the consent form were enrolled in the study. all study protocols 
were carried out in accordance with the declaration of Helsinki [24]. 
 
Statistical analysis 
Statistical analysis was performed using IBM SPSS version 20.0 (IBM Corp., Armonk, 
NY, USA). Categorical data were evaluated in terms of frequency and percentage, and 
continuous data were presented as means ± standard deviation. Chi-square test was used 
to compare the prevalence of osteoporosis and osteopaenia between two groups. The 
variables were compared using two-sample t-test. Pearson correlation analysis was used 
to estimate the relationship of thyroid hormones with Z-scores of BMD and BTMs. The 
odds ratios (ORs) and 95% confidence intervals (CIs) for FT3, FT4, and TSH, in 
association with Z-scores of BMD, iPTH, P1NP, CTX-1, Ca, P, vitamin D (3), and ALP 
were analysed using multivariate logistic regression. The p-value < 0.05 was considered 
as statistically significant. 
Results 
Laboratory characteristics of the two study groups  
The descriptive statistics of the characteristics were shown in Table I. In DTC subjects, 
serum TSH levels were lower, serum FT4, P1NP, CTX-1, and ALP levels were higher 
compared with controls. There were no significant differences in age, Z-scores of BMD, 
serum FT3, iPTH, Ca, P, and vitamin D (3) levels between the two study groups.  
Table I. Comparison of characteristics between the group with differentiated thyroid 
cancer (DTC) and the control group 
Characteristics 
Control group 
(n = 50) 
DTC group 
(n = 65) 
p-value 
FT3 [pmol/L] 4.12 ± 1.03 4.15 ± 1.09 t = 0.15, p = 0.881 
FT4 [pmol/L] 13.12 ± 3.56 14.59 ± 4.07* 
t = 2.026, p = 
0.045 
TSH [mIU/L] 1.65 ± 1.45 0.35 ± 0.14* 
t = −7.194, p < 
0.001 
iPTH [mIU/L] 15.75 ± 6.48 16.15± 4.22 t = 0.399, p = 0.69 
Ca [mmol/L] 2.46 ± 0.34 2.44±0.26 
t = − 0.358, p = 
0.721 
P [mmol/L] 1.12 ± 0.25 1.15 ± 0.36 
t = 0.503, p = 
0.616 
ALP [IU/L] 95.15 ± 21.26 104.13 ± 18.43* 
t = 2.422, p = 
0.017 
CTX-1 [ng/mL] 0.24 ± 0.13 0.31 ± 0.16* 
t = 2.519, p = 
0.013 
P1NP [ug/L] 24.40 ± 11.41 29.87 ± 15.53* 
t = 2.093, p = 
0.039 
Vitamin D (3) [ug/L] 19.40 ± 3.22 18.8 ± 3.47 
t = − 0.948, p = 
0.345 
Mean Z-scores of 
lumbar BMD 
− 0.91 ± 0.98 − 0.94 ± 1.32 
t = − 0.1346, p = 
0.893 
Mean Z-scores of hip − 0.92 ± 1.09 − 0.91 ± 1.76 t = 0.073, p = 
BMD 0.942 
FT3 — free triiodothyronine; FT4 — free thyroxine; TSH — thyroid-stimulating hormone; iPTH — 
intact parathyroid hormone; Ca — calcium; P — phosphorus; ALP — alkaline phosphatase; CTX-1 — 
C-terminal telopeptide of type 1 collagen; P1NP — N-terminal propeptide of type 1 N procollagen; BMD 
— bone mineral density. Variables were presented as means ± standard deviations. *significantly different 
(p < 0.05) from control group 
 
Prevalence of low BMD in the study groups 
The prevalence of low BMD was higher in the DTC group than in the control group. A 
comparison of prevalence of low BMD between the two groups is shown in Table II.  
Table II. A comparison of the prevalence of low bone mineral density (BMD) between 
subjects with differentiated thyroid cancer (DTC) and controls 
Diseases/Quantity 
(percent) 
DTC group 
(n = 65) 
Control group 
(n = 50) 
Statistical 
significance 
Low BMD 29 (44.62%) 14 (28%) 
x2 = 4.736,  
p = 0.030 
OR = 2.406,  
95% CI: 1.083–
5.345 
OR — odds ratio; CI — confidence interval 
 
The relationship of serum thyroid hormone levels with Z-scores of BMD and 
BTMs  
We found no obvious associations between serum FT3, FT4, and TSH levels and Z-
scores of BMD, iPTH, P1NP, CTX-1, Ca, P, vitamin D (3), and ALP in controls. 
Similarly, there were no significant associations between serum FT3, FT4 levels, and 
the above parameters in the DTC group. Serum TSH levels were negatively associated 
with CTX-1 and ALP. There were no associations of serum TSH levels with Z-scores 
of BMD and other BTMs. Correlation analysis between serum thyroid hormone levels 
and Z-scores of BMD and BTMs in the DTC group are shown in Table III. 
Table III. Correlation coefficients (r values) between serum thyroid hormones levels 
and T-scores of bone mineral density (BMD) and bone turnover markers (BTMs) in 
subjects with differentiated thyroid cancer (DTC) 
Variables FT3 FT4 TSH 
Mean Z scores of 
lumbar BMD  
r = −0.153 
p = 0.221 
r = −0.156 
p = 0.198 
r = 0.141 
p = 0.231 
Mean Z scores of 
hip BMD  
r = −0.095 
p = 0.47 
r = −0.103 
p = 0.461 
r = 0.098 
p = 0.491 
iPTH 
r = 0.093 
p = 0.484 
r = 0.113 
p = 0.447 
r = − 0.221 
p = 0.068 
Ca 
r = 0.168 
p = 0.182 
r = 0.093 
p = 0.484 
r = 0.098 
p = 0.493 
P 
r = 0.132 
p = 0.308 
r = 0.166 
p = 0.173 
r = − 0.102 
p = 0.463 
Vitamin D (3) 
r = −0.125 
p = 0.387 
r = −0.096 
p = 0.464 
r = 0.190 
p = 0.131 
ALP 
r = 0.126 
p = 0.429 
r = －0.095 
p = 0.472 
r = −0.278 
*p = 0.02 
CTX-1 r = 0.209 r = 0.152 r = −0.363 
p = 0.089 p = 0.298 *p = 0.002 
P1NP 
r = 0.198 
p = 0.10 
r = 0.215 
p = 0.073 
r = −0.127 
p = 0.440 
FT3 — free triiodothyronine; FT4 — free thyroxine; TSH — thyroid-stimulating hormone; iPTH — 
intact parathyroid hormone; Ca — calcium; P — phosphorus; ALP — alkaline phosphatase; CTX-1 — 
C-terminal telopeptide of type 1 collagen; P1NP — N-terminal propeptide of type 1 N procollagen; *The 
p-value at < 0.05 was considered as statistically significant 
 
Analysing the relationship of serum thyroid hormones levels and Z-scores of BMD 
and BTMs using multivariate logistic regression 
After adjusting for age, serum TSH levels negatively associated with CTX-1 and ALP, 
not with Z-scores of BMD, iPTH, P1NP, Ca, P, and vitamin D (3). Serum FT3 and FT4 
levels did not associate with Z-scores of BMD and BTMs. Serum TSH levels, in 
associations with Z-scores of BMD and BTMs using multivariate logistic regression in 
all participants, are shown in Table IV.  
Table IV. Serum thyroid-stimulating hormone (TSH) levels in association with T-scores 
of (bone mineral density) BMD and (bone turnover markers) BTMs using multivariate 
logistic regression 
Variables p-value OR 95% CI 
Mean Z-scores of 
lumbar BMD 
0.121 1.098 1.105–4.245 
Mean Z-scores of 
hip BMD  
0.083 1.419 1.412–3.473 
iPTH 0.159 1.003 1.045–1.493 
Ca 0.179 1.142 1.259–5.317 
P 0.428 1.001 1.033–2.756 
Vitamin D (3) 0.317 1.018 1.153–3.628 
ALP *0.016 1.432 0.998–6.619 
CTX-1 *0.023 1.323 0.953–3.728 
P1NP 0.073 1.006 0.993–2.284 
OR — odds ratio; CI — confidence interval; iPTH — intact parathyroid hormone; Ca — calcium; P — 
phosphorus; ALP — alkaline phosphatase; CTX-1 — C-terminal telopeptide of type 1 collagen; P1NP 
— N-terminal propeptide of type 1 N procollagen. *The p-value at < 0.05 was considered statistically 
significant 
 
Discussion 
The purpose of this study was to investigate the impact of long-term TSH suppression 
treatment on BMD and BTMs in premenopausal women with thyroid cancer after total 
or near total thyroidectomy. In this study, we selected iPTH, P1NP, CTX-1, Ca, P, 
vitamin D (3), and ALP as evaluation indices of BTMs.  
The effect of TSH suppression therapy on BMD in premenopausal subjects who 
underwent thyroidectomy remains controversial. The majority of studies suggested no 
effect of TSH suppression therapy on BMD in premenopausal women and men [25–
27]. In this study, we failed to find a change in BMD in these premenopausal women 
with long-term TSH suppression therapy. The main reason is probably that 
premenopausal women are not at high risk for reduced bone density due to the effects 
of oestrogen. Oestrogen plays an important role in the growth and maturation of bone 
as well as in the regulation of bone formation and turnover in adult bone [28].  
We demonstrated that in premenopausal women with DTC who had received at least 
one year of TSH suppression treatment, serum P1NP, CTX-1, and ALP levels were 
higher compared with controls. TSH suppression therapy in DTC patients after 
thyroidectomy can induce subclinical hyperthyroidism, especially in the first two years; 
the serum TSH levels are required to be less than 0.1 mIU/L. Elevated thyroid hormones 
can stimulate bone turnover and bone resorption, thus leading to reduced bone strength, 
destruction of bone structure, and increased risk of fractures [29]. In this study, 
increased serum levels of P1NP, CTX-1, and ALP in DTC patients mean increased 
bone turnover and decreased bone quality.  
In this study, we found higher prevalence of low BMD among premenopausal DTC 
women who received long-term LT4 therapy. Osteoporosis is less common in 
premenopausal women than in postmenopausal women. The main reason is the 
protective effect of oestrogen in premenopausal women who are less likely to develop 
osteoporosis. The WHO and International Society for Clinical Densitometry (ISCD) 
suggest the use of the Z scores of BMD rather than T scores in the diagnosis of low 
BMD, and the diagnosis of osteoporosis in premenopausal women is secure only when 
there is a history of low trauma fracture [30]. Some large population-based cohort 
studies showed that the risk of osteoporosis and fracture increased in patients receiving 
TSH suppression therapy. They also found that the high cumulative doses of 
levothyroxine were significantly associated with an increased risk of osteoporosis and 
fracture[31,32]. However, these conclusions were all based on postmenopausal women. 
Meanwhile, we found that the serum TSH levels were negatively associated with CTX-
1 and ALP, but not with BMD. These results showed that TSH suppressive therapy only 
increased bone turnover to a certain extent. Moreover, the degree of TSH inhibition was 
correlated to the degree of changes of bone turnover. The previous data of suppressive 
doses of levothyroxine therapy on bone mass and bone turnover in premenopausal 
women are limited. However, some studies on hypothyroid premenopausal women with 
long-term levothyroxine therapy showed increased bone turnover and increased 
resorptive changes, but not osteoporosis [33–35]. Hyperthyroid patients also have 
serum BTMs concentrations significantly higher in comparison with euthyroid subjects, 
in relation to thyroid hormones excess and high bone turnover[36]. Therefore, it is of 
great significance to evaluate the bone metabolism status in premenopausal patients 
with thyroid cancer after receiving long-term levothyroxine therapy, which can prevent 
osteopaenia or osteoporosis in the future through intervention treatment. 
One limitation of our study was that the sample size was small. A larger cohort is needed 
to investigate if the serum TSH levels in premenopausal women receiving long-term 
levothyroxine treatment correlate with BMD and BTMs. In different periods after 
thyroid cancer surgery, there are different standards for the control of serum TSH levels 
[37]. Moreover, despite clinical practice guidelines for the management of DTC, there 
are no recommendations on rational serum TSH levels to prevent cancer recurrences 
and improve survival11. Therefore, in future studies, groups can be divided according 
to serum TSH levels, so as to more accurately judge the impact of TSH inhibition 
therapy on changes of bone metabolism.  
 
Conclusions 
We found a high prevalence of low BMD among premenopausal DTC women who 
received long-term LT4 therapy after thyroidectomy. In these patients, serum TSH 
levels were negatively associated with CTX-1 and ALP. Long-term TSH suppression 
therapy was a significant risk factor for decreased bone strength, mainly by increasing 
bone turnover. 
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